Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 553

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Cardioprotective interventions for cancer patients receiving anthracyclines

Open access
van Dalen, Elvira C, Caron, Huib N, Dickinson, Heather O, Kremer, Leontien CM·2011·Cochrane Database of Systematic Reviews
DOI 10.1002/14651858.cd003917.pub4
Open this paper in CoChat — free account

Abstract

BACKGROUND: Anthracyclines are among the most effective chemotherapeutic agents in the treatment of numerous malignancies. Unfortunately, their use is limited by a dose-dependent cardiotoxicity. In an effort to prevent this cardiotoxicity, different cardioprotective agents have been studied. OBJECTIVES: The objective of this review was to assess the efficacy of different cardioprotective agents in preventing heart damage in cancer patients treated with anthracyclines. SEARCH STRATEGY: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2010, Issue 10), MEDLINE (1966 to November 2010) and EMBASE (1980 to November 2010) databases. In addition, we handsearched reference lists, conference proceedings of the International Society of Paediatric Oncology (SIOP) and American Society of Clinical Oncology (ASCO) meetings (1998 to 2010) and ongoing trials registers. SELECTION CRITERIA: Randomised controlled trials (RCTs) in which any cardioprotective agent was compared to no additional therapy or placebo in cancer patients (children and adults) receiving anthracyclines. DATA COLLECTION AND ANALYSIS: Two review authors independently performed the study selection, risk of bias assessment and data extraction including adverse effects. MAIN RESULTS: We identified RCTs for the eight cardioprotective agents N-acetylcysteine, phenethylamines, coenzyme Q10, a combination of vitamins E and C and N-acetylcysteine, L-carnitine, carvedilol, amifostine and dexrazoxane (mostly for adults with advanced breast cancer). All studies had methodological limitations and for the first seven agents there were too few studies to allow pooling of results. None of the individual studies showed a cardioprotective effect. The 10 included studies on dexrazoxane enrolled 1619 patients. The meta-analysis for dexrazoxane showed a statistically significant benefit in favour of dexrazoxane for the occurrence of heart failure (risk ratio (RR) 0.29, 95% CI 0.20 to 0.41). No evidence was found for a difference in response rate or survival between the dexrazoxane and control groups. The results for adverse effects were ambiguous. No significant difference in the occurrence of secondary malignancies was identified. AUTHORS' CONCLUSIONS: No definitive conclusions can be made about the efficacy of cardioprotective agents for which pooling of results was impossible. Dexrazoxane prevents heart damage and no evidence for a difference in response rate or survival between the dexrazoxane and control groups was identified. The evidence available did not allow us to reach any definite conclusions about adverse effects. We conclude that if the risk of cardiac damage is expected to be high, it might be justified to use dexrazoxane in patients with cancer treated with anthracyclines. However, clinicians should weigh the cardioprotective effect of dexrazoxane against the possible risk of adverse effects for each individual patient.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd003917.pub4

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 55 references

Research works printed but not linked: 49

  1. Galetta, 2005, Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients, Biomedicine & Pharmacotherapy, 59, 541, 10.1016/j.biopha.2004.12.003 · doi:10.1016/j.biopha.2004.12.003
  2. Gallegos-Castorena, 2007, Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin, Pediatric Hematology and Oncology, 24, 403, 10.1080/08880010701451244 · doi:10.1080/08880010701451244
  3. Kraft, 1990, Effects of verapamil on anthracycline-induced cardiomyopathy: preliminary results of a prospective multicenter trial, Haematology and Blood Transfusion, 33, 566, 10.1007/978-3-642-74643-7_103 · doi:10.1007/978-3-642-74643-7_103
  4. Milei, 1987, Prevention of adriamycin-induced cardiotoxicity by prenylamine: a pilot double blind study, Cancer Drug Delivery, 4, 129, 10.1089/cdd.1987.4.129 · doi:10.1089/cdd.1987.4.129
  5. Myers, 1983, A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine, Seminars in Oncology, 10 Suppl 1, 53
  6. Swain, 1997, Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer, Journal of Clinical Oncology, 15, 1318, 10.1200/JCO.1997.15.4.1318 · DOI · Paper page
  7. Wagdi, 1995, Cardioprotection during chemo-and radiotherapy of malignant diseases - an echocardiographic pilot study, Schweizerische Rundschau fur Medizin (Praxis), 84, 1220
  8. Bates, 1997, A pharmacoeconomic evaluation of the use of dexrazoxane in preventing anthracycline-induced cardiotoxicity in patients with stage IIIB or IV metastatic breast cancer, Clinical Therapeutics, 19, 167, 10.1016/S0149-2918(97)80084-7 · doi:10.1016/s0149-2918(97)80084-7
  9. Batist, 1985, Cardiac and red blood cell glutathione peroxidase: results of a prospective randomized trial in patients on total parenteral nutrition, Cancer Research, 45, 5900
  10. Judy, 1984, Coenzyme Q10 reduction of adriamycin cardiotoxicity, 4, 231
  11. Massidda, 1997, Early detection of the anthracycline-induced cardiotoxicity. A non-invasive haemodynamic study, Anticancer Research, 17, 663
  12. Michelotti, 2000, Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients, Breast Cancer Research and Treatment, 59, 133, 10.1023/A:1006394801389 · doi:10.1023/a:1006394801389
  13. Nakamae, 2005, Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone, Cancer, 104, 2492, 10.1002/cncr.21478 · doi:10.1002/cncr.21478
  14. Neto, 2006, Left ventricular systolic function assessed by echocardiography in children and adolescents with osteosarcoma treated with doxorubicin alone or in combination with dexrazoxane, Arquivos Brasileiros de Cardiologia, 87, 699
  15. Paiva, 2005, Cardioprotective effect of dexrazoxane during treatment with doxorubicin: a study using low-dose dobutamine stress echocardiography, Pediatric Blood and Cancer, 45, 902, 10.1002/pbc.20488 · doi:10.1002/pbc.20488
  16. Piccinini, 1987, Protective effect of trimetazidine on the cardiotoxicity of doxorubicin, Concours Medical, 109, 3479
  17. Rosenfeld, 1992, Prevention of adriamycin cardiomyopathy with dexrazoxane (ADR-529, ICRF-187), Proceedings of ASCO, 11, 62
  18. Speyer, 1990, A prospective randomized trial of ICRF-187 for prevention of cumulative doxorubicin-induced cardiac toxicity in women with breast cancer, Cancer Treatment Reviews, 17, 161, 10.1016/0305-7372(90)90041-D · doi:10.1016/0305-7372(90)90041-d
  19. Tallarico, 2003, Myocardial cytoprotection by trimetazidine against anthracycline-induced cardiotoxicity in anticancer chemotherapy, Angiology, 54, 219, 10.1177/000331970305400212 · doi:10.1177/000331970305400212
  20. Bokkel-Huinink, 1990, ICRF 187 protects against doxorubicin induced cardiomyopathy, Annals of Oncology, 1, 106
  21. Tonkin, 1996, Dexrazoxane cardioprotection for patients receiving FAC chemotherapy: a pharmacoeconomic evaluation, Annals of Cancer Control Research, 6, 458
  22. Unverferth, 1983, Attempt to prevent doxorubicin-induced acute human myocardial morphologic damage with acetylcysteine, Journal of the National Cancer Institute, 71, 917
  23. Vici, 1998, Dexrazoxane cardioprotection in advanced breast cancer patients undergoing high-dose epirubicin treatment, La Clinica Terapeutica, 149, 15
  24. Wagdi, 1996, Cardioprotection in patients undergoing chemo-and/or radiotherapy for neoplastic disease: a pilot study, Japanese Heart Journal, 37, 353, 10.1536/ihj.37.353 · doi:10.1536/ihj.37.353
  25. Weisberg, 1992, Dexrazoxane (ADR-529, ICRF-187, Zinecard) protects against doxorubicin induced chronic cardiotoxicity, Proceedings of ASCO, 11, 91
  26. Weitzman, 1980, Prospective study of tocopherol prophylaxis for anthracycline cardiac toxicity, Current Therapeutic Research, 28, 682
  27. Whittaker, 1984, Effect of digoxin and vitamin E in preventing cardiac damage caused by doxorubicin in acute myeloid leukaemia, British Medical Journal, 288, 283, 10.1136/bmj.288.6413.283-a · doi:10.1136/bmj.288.6413.283-a
  28. Whittaker, 1987, Doxorubicin cardiotoxicity: attempts at prevention with digoxin and alpha-tocopherol (vitamin E), Clinical Trials Journal, 24 Suppl 1, 45
  29. Cardenas, 2003, Effectiveness and safety of dexrazoxane as a cardioprotector in Mexican children with cancer, Medical and Pediatric Oncology, 41, PL001
  30. De Berranger E Results of randomized study on dexrazoxane administration in children with de novo acute leukemia ASCO Annual Meeting (abstract number 9037) 2006 · doi:10.1200/jco.2006.24.18_suppl.9037
  31. Gu, 2010, Clinical observation of hydroprednisone and glutathione in chemotherapy of breast cancer, Chinese Journal of Cancer Prevention and Treatment, 17, 131
  32. Jackowska, 2003, Assessment of dexrazoxane tolerance in leukemic children receiving anthracyclines, Medical and Pediatric Oncology, 41, PD003
  33. Saad El-Din, 2003, A randomized clinical trial to evaluate cardioprotective effect of ICRF-187 in children with acute lymphoblastic leukemia, Medical and Pediatric Oncology, 41, O109
  34. Bokkel-Huinink, 1992, ICRF 187 protects against doxorubicin induced cardiomyopathy, Annals of Oncology (abstract number 221), 114
  35. Barry, 2008, Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane, Journal of Clinical Oncology, 26, 1106, 10.1200/JCO.2007.12.2481 · DOI
  36. Leonardis, 1985, Reduction of cardiac toxicity of anthracyclines by L-Carnitine: preliminary overview of clinical data, International Journal of Clinical Pharmacology Research, 5, 137
  37. Garbrecht, 1986, Verapamil in the prevention of adriamycin-induced cardiomyopathy, Klinische Wochenschrift, 64 Suppl VII, 132
  38. Guthrie, 1977, Doxorubicin cardiotoxicity: possible role of digoxin in its prevention, British Medical Journal, 2, 1447, 10.1136/bmj.2.6100.1447 · doi:10.1136/bmj.2.6100.1447
  39. Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated September 2006] John Wiley & Sons, Ltd
  40. Hofmann, 1993, A questionnaire suitable for general practice for detection of the health status and quality of life of patients with hemato-oncologic diseases: psychometric properties. The study G "quality of life" of the International Society for Chemo-and Immunotherapy (I.G.C.I.), Wiener Klinische Wochenschrift, 105, 277
  41. Kawasaki, 1992, Polyoxyethylene-modified superoxide dismutase reduces side effects of adriamycin and mitomycin C, Japanese Journal of Cancer Research, 83, 899, 10.1111/j.1349-7006.1992.tb01997.x · doi:10.1111/j.1349-7006.1992.tb01997.x
  42. Legha, 1982, Clinical and pharmacologic investigation of the effects of a-tocopherol on adriamycin cardiotoxicity, Annals of the New York Academy of Sciences, 393, 411, 10.1111/j.1749-6632.1982.tb31279.x · doi:10.1111/j.1749-6632.1982.tb31279.x
  43. Lipshultz, 1998, 48 hour continuous doxorubicin infusion is not cardioprotective in children assessed 18 months later: the DFCI 91001 ALL protocol, Proceedings of the American Society of Clinical Oncology, 17, 528a
  44. Lipshultz, 2010, Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial, Lancet Oncology, 11, 950, 10.1016/S1470-2045(10)70204-7 · DOI · Paper page
  45. Muggia, 1991, New anthracycline antitumor antibiotics, Critical Reviews in Oncology/Hematology, 11, 43, 10.1016/1040-8428(91)90017-7 · doi:10.1016/1040-8428(91)90017-7
  46. Odaimi, 1987, High-dose chemotherapy, American Journal of Clinical Oncology, 10, 123, 10.1097/00000421-198704000-00045 · doi:10.1097/00000421-198704000-00045
  47. Pierga, 2001, Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patients, Annals of Oncology, 12, 231, 10.1023/A:1008330527188 · doi:10.1023/a:1008330527188
  48. Dalen, 2011, Should anthracyclines and dexrazoxane be used for children with cancer?, Lancet Oncology, 12, 12, 10.1016/S1470-2045(10)70301-6 · doi:10.1016/s1470-2045(10)70301-6
  49. Dalen, 2008, Cardioprotective interventions for cancer patients receiving anthracyclines, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD003917.pub3 · DOI

Cited by

See all 553

Metadata

Authors
van Dalen, E. C., Caron, H. N., Dickinson, H. O., & Kremer, L. C.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2011-06-15
Volume
2016
Issue
9
Pages
CD003917-CD003917
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
DOI
10.1002/14651858.cd003917.pub4
OpenAlex
W2150475243
Cited by
553
References
55
FWCI
26.45
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cardioprotective interventions for cancer patients receiving anthracyclines. https://app.cochat.ai/papers/10.1002/14651858.cd003917.pub4
The paper
van Dalen, E. C., Caron, H. N., Dickinson, H. O., & Kremer, L. C. (2011). Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd003917.pub4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.